The FXR agonist tropifexor is also being investigated in combination with the SGLT-1/2 inhibitor licogliflozin in NASH patients with varying stages of liver fibrosis (NCT04065841) [145]. This evidence concerns the gene SLC5A1 and metabolic dysfunction-associated steatohepatitis.